Related Experiment Videos
Mechanism of action of anti-inflammatory drugs
1William Harvey Research Institute, St Bartholomew's Hospital Medical College, London, UK.
Abstract:
Cyclooxygenase (COX) is the pivotal enzyme in prostaglandin biosynthesis. It exists in two isoforms, constitutive COX-1 (responsible for physiological functions) and inducible COX-2 (involved in inflammation). Inhibition of COX explains both the therapeutic effects (inhibition of COX-2) and side effects (inhibition of COX-1) of non-steroidal anti-inflammatory drugs (NSAIDs). A NSAID which selectively inhibits COX-2 is likely to retain maximal anti-inflammatory efficacy combined with less toxicity. The activity of a number of NSAIDs has been investigated in several test systems, showing that most of those marketed have higher activities against COX-1 or are equipotent against both isoforms. Adverse event data of marketed NSAIDs show a relationship between a poor safety profile and more potent inhibition of COX-1 relative to COX-2. There are several new non-steroidal COX-2 inhibitors in development. The most clinically advanced is meloxicam, which consistently demonstrates higher activity against COX-2 than COX-1 in several test systems.
Insights
Selective cyclooxygenase-2 (COX-2) inhibitors offer potential anti-inflammatory benefits with reduced toxicity. Meloxicam, a leading non-steroidal anti-inflammatory drug (NSAID), shows greater activity against COX-2 than COX-1.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Development
Background:
- Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, are central to prostaglandin synthesis.
- COX-1 is constitutively expressed for physiological functions, while COX-2 is induced during inflammation.
- Non-steroidal anti-inflammatory drugs (NSAIDs) exert therapeutic and adverse effects through COX inhibition.
Purpose of the Study:
- To evaluate the therapeutic potential of selective COX-2 inhibitors.
- To correlate NSAID activity profiles with safety and efficacy.
- To assess the development of novel non-steroidal COX-2 inhibitors.
Main Methods:
- Investigated the activity of various NSAIDs across multiple test systems.
- Analyzed adverse event data for marketed NSAIDs.
- Examined the COX-1 versus COX-2 activity of meloxicam.
Main Results:
- Most marketed NSAIDs inhibit COX-1 or are equipotent against both isoforms.
- A poor safety profile in NSAIDs correlates with potent COX-1 inhibition.
- Meloxicam demonstrates consistently higher activity against COX-2 compared to COX-1.
Conclusions:
- Selective COX-2 inhibition is a promising strategy for maximizing anti-inflammatory efficacy while minimizing toxicity.
- NSAIDs with a higher relative activity against COX-2 may offer improved safety profiles.
- Meloxicam represents a clinically advanced non-steroidal COX-2 inhibitor with potential therapeutic advantages.